/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos · Aug 26, 2026

Experts discuss the evolving bladder cancer landscape, focusing on EVP for MIBC and novel intravesical therapies like TAR-200 for NMIBC.

Oncologists Adopt EVP Neoadjuvant Therapy for Cisplatin-Eligible Patients Ahead of Formal Data Release

Some clinicians are already using enfortumab vedotin plus pembrolizumab (EVP) for cisplatin-eligible patients off-trial, driven by promising early data and patient preference. This practice contrasts with a more "purist" approach of waiting for full trial results, highlighting a real-world tension between early adoption and strict adherence to evidence-based guidelines.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago

Urologists Increasingly Deem Elderly Patients Unsuitable for Radical Cystectomy, Driving Non-Surgical Approaches

There's a significant shift in urological practice where high-risk patients, such as an 80-year-old, are now often considered non-candidates for radical cystectomy due to the procedure's high morbidity. This change from the surgical side is a key driver for exploring bladder-preserving treatments like chemoradiation or novel systemic therapies.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago

Variant Bladder Cancer Histologies Create Uncertainty for Novel Nectin-Targeted Therapies

Even as therapies like enfortumab vedotin (EV) become standard, clinicians express uncertainty about their efficacy in patients with variant histologies. Some variants exhibit low or no expression of nectin, the drug's target, raising concerns about treatment suitability and highlighting a critical knowledge gap where traditional platinum-based chemotherapy may still be preferred.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago

TAR-200 May Displace BCG as Frontline Bladder Cancer Therapy Due to Shortages and Physician Adoption

The upcoming Sunrise 3 trial is positioned to potentially replace BCG as the standard frontline intravesical therapy. Beyond superior efficacy, a key driver for this shift would be the chronic global BCG shortage and physicians' eagerness to adopt effective alternatives, mirroring the rapid adoption of new agents in the neoadjuvant setting.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago

Intravesical FGFR Inhibitor TAR-210 Offers Efficacy Without Systemic Toxicity of Oral Drugs

The development of TAR-210, an intravesical device delivering erdafitinib, exemplifies a key trend: achieving targeted therapy efficacy while avoiding debilitating systemic side effects. With a hundred-fold lower systemic drug absorption compared to its oral counterpart, this approach provides the "best of both worlds" for biomarker-driven, non-muscle-invasive bladder cancer.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago